CLINICAL SIGNIFICANCE OF METHYLATION OF LNCRNA GENES GAS5, ZEB1-AS1 IN TUMORS OF PATIENTS WITH BREAST CANCER
- 12 November 2025
- journal article
- Published by Russian Vrach, Publishing House Ltd. in Problems of Biological, Medical and Pharmaceutical Chemistry
- p. 59-67
Abstract
Introduction. Long non-coding RNAs (LncRNAs) are transcripts whose role in carcinogenesis is poorly understood. LncRNA expression determines the biological properties of a cell, including invasive potential and ability to migrate. Methylation status changes lncRNA functions and can be a marker of tumor prognosis. The aim of the work is study the methylation frequency of the LncRNA genes GAS5, ZEB1-AS1 in breast cancer and to evaluate the clinical signifi-cance. Material and methods. 140 patients with breast cancer were examined, mainly with T1 – (38.7%) and T2 – (55.6%) stages, N0 status – (54.0%), N1 status – (37.9%). Luminal type of breast cancer – 80% (n = 113), non-luminal – 20% (n = 27). Morphologically: invasive ductal carcinoma (77.1%), G2 differentiation (62.9%) were predominantly detected. Methylation of CpG regions of promoter regions of the GAS5, ZEB1-AS1 lncRNAs genes in paired tumor and histologically unaffected breast tissue samples was studied using the methyl-specific PCR method. The T100 amplifier (Bio-Rad, USA) and Lasergene 17.1 primers from DNASTAR (USA) were used in the work. Statistical data processing was performed in the SPSS, v. 23 program. Results. The frequency of methylation of the GAS5, ZEB1-AS1 genes in the tumor is higher than in histologically unaffected breast tissue. Gene meth-ylation is associated with age, R = 0.43 (GAS5) and R = 0.26 (ZEB1-AS1), and increases the stage tumor process. A correlation was established be-tween GAS5 gene methylation and the T index (R = 0.21, p < 0.05), N status (R = 0.31, p < 0.05). There is an inverse correlation with the biological subtype of luminal cancer (R = –0.29, p < 0.05). The absence of methylation of the GAS5 and ZEB1-AS1 genes is associated with a decrease in 5-year overall survival and 10-year progression-free survival in breast cancer. Conclusions. In breast cancer, methylation of the lncRNAs GAS5, ZEB1-AS1 genes in the tumor exceeds that in the unchanged breast tissue. The methylation status of the genes GAS5, ZEB1-AS1 is associated with the stage, tumor size, regional metastasis, and does not affect the long-term treatment results.Keywords
This publication has 19 references indexed in Scilit:
- Non-coding RNAs, a double-edged sword in breast cancer prognosisCancer Cell International, 2025
- Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive reviewDiscover Oncology, 2025
- Hypermethylation of Genes in New Long Noncoding RNA in Ovarian Tumors and Metastases: A Dual EffectBulletin of Experimental Biology and Medicine, 2021
- Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancerInternational Immunopharmacology, 2020
- Long non-coding RNA IGF2-AS represses breast cancer tumorigenesis by epigenetically regulating IGF2Experimental Biology and Medicine, 2020
- Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapyBreast Cancer Research, 2019
- Immunotherapy and targeted therapy combinations in metastatic breast cancerThe Lancet Oncology, 2019
- LncRNA ZEB1-AS1 expression in cancer prognosis: Review and meta-analysisClinica Chimica Acta, 2018
- Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA lossGenes & Development, 2015
- Methylation of the RASSF1A promoter region and the allelic imbalance frequencies in chromosome 3 critical regions correlate with progression of clear cell renal carcinomaMolecular Biology, 2009